Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Apollohosp Ltd — Q3 FY25
Apollo Hospitals delivered a strong Q3 FY25 with consolidated revenue of INR 5,527 crore (+14% YoY) and EBITDA of INR 762 crore (+24% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Apollo Hospitals delivered a strong Q3 FY25 with consolidated revenue of INR 5,527 crore (+14% YoY) and EBITDA of INR 762 crore (+24% YoY). PAT surged 52% YoY to INR 372 crore, driven by mid-teens growth across all segments and margin expansion in healthcare services (24.1% EBITDA margin). The hospital business saw 13% revenue growth, with high-margin CONGO specialties (cardiac, oncology, neuro, gastro, ortho) growing at 10.35% volume, offsetting a 1.5% revenue drag from Bangladesh patient decline. Apollo HealthCo (pharmacy & digital) grew 15% YoY, with digital losses narrowing. Management guided for calibrated bed additions (1,737 beds over FY26-27) with minimal margin impact (~100 bps), and expects Apollo 24/7 to break even by Q2/Q3 FY26. Key risk: slower-than-expected recovery in Bangladesh patient inflows and competitive pressure in digital pharmacy.
अपोलो हॉस्पिटल्स ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कुल कमाई 5,527 करोड़ रुपये रही, जो पिछले साल से 14% ज्यादा है। कंपनी की कमाई और खर्च के बीच का अंतर (EBITDA) 762 करोड़ रुपये रहा, जो 24% बढ़ा। मुनाफा (PAT) 372 करोड़ रुपये हो गया, जो 52% ज्यादा है। यह सभी कारोबारों में अच्छी बढ़त और अस्पताल सेवाओं में मुनाफा बढ़ने से हुआ। दिल, कैंसर, दिमाग, पेट और हड्डी जैसी बीमारियों के इलाज में 10.35% ज्यादा मरीज आए। बांग्लादेश से मरीज कम आने से थोड़ा नुकसान हुआ। फार्मेसी और डिजिटल कारोबार (Apollo HealthCo) 15% बढ़ा। कंपनी अगले दो साल में 1,737 नए बिस्तर जोड़ेगी, जिससे मुनाफे पर थोड़ा असर पड़ेगा। Apollo 24/7 अगले साल की दूसरी-तीसरी तिमाही तक घाटा खत्म कर सकता है। मुख्य जोखिम: बांग्लादेश से मरीजों की कमी और डिजिटल फार्मेसी में प्रतिस्पर्धा।
Promises0 met · 1 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
Bangladesh patient decline persists
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
CONGO Volume Growth
10.35%
+10.35pp YoY
Cardiac, oncology, neuro, gastro, ortho volumes grew at more than double the overall IP volume growth of 5%.
ARPOB
INR 60,839
+8% YoY
Average revenue per occupied bed improved due to better case mix and payer mix.
Group Occupancy
68%
+2pp YoY
Occupancy improved from 66% in Q3 FY24, driven by higher volumes and efficiency.
Apollo 24/7 GMV
INR 760 crore
+11% YoY
Platform GMV grew 11% YoY, with daily active users up 25%.
What Changed vs Last Quarter
NEW
Apollo 24/7 break-even by Q2/Q3 FY26
Digital platform expected to achieve EBITDA break-even by end of Q2 or Q3 of next fiscal year, with GMV target of INR 900-1,000 crore.
NEW
Hospital margin trajectory ~24% despite new beds
Healthcare services EBITDA margin expected to remain around 24% next year, with new bed openings impacting margins by no more than 100 bps.
NEW
New hospital commissioning schedule
Pune and Kolkata hospitals to open in H1 FY26; Hyderabad and Gurugram by end of FY26; 50% of 1,737 beds operational in FY26, rest in FY27.
UPDATED
HealthCo revenue target of INR 25,000 crore by FY27
Apollo HealthCo (including Keimed) targets INR 25,000 crore revenue and 7-8% EBITDA margin by FY27.
DROPPED
1,400 new beds in FY26 with phased operationalization
Six facilities in key metros will be commissioned in FY26; half of the beds operationalized in FY26, rest in FY27 to protect margins.
DROPPED
Apollo HealthCo online segment breakeven in 5-6 quarters
The online 24/7 platform is expected to achieve breakeven by Q2 FY26, with sustainable GMV growth and reduced marketing spend.
DROPPED
Healthcare services margin expansion of 50-60 bps in FY25
Management expects 50-60 bps margin expansion for the full year, lower than initial 100-150 bps due to Bangladesh headwinds.
NEW RISK
Bangladesh patient decline persists
Bangladesh patient footfall dropped, causing 1.5% revenue impact; management is exploring other international markets but recovery timeline uncertain.
NEW RISK
Digital pharmacy competitive pressure
Analyst raised concerns about high ESOP costs and competition from startups; management acknowledged but defended ESOP as retention tool.
NEW RISK
New bed ramp-up risk
Large capacity addition (1,737 beds) could pressure margins if occupancy ramps slower than expected; management expects 100 bps margin impact.
RISK GONE
Bangladesh patient flow disruption
International patient revenue from Bangladesh fell 27% in H1, impacting Tamil Nadu volumes. Recovery expected but uncertain.
RISK GONE
Quick commerce competition pressuring 24/7 GMV
Quick commerce players are impacting non-Rx sales, delaying unit economics improvement. Management is rolling out 19-min delivery to counter.
RISK GONE
Insurance payer pushback on pricing
Health insurers facing high claims ratios may exert pressure on hospital pricing. Management believes network strength mitigates this.
RISK GONE
New bed commissioning may pressure margins
1,400 new beds in FY26 could drag EBITDA margins by 1-1.2% during ramp-up, though management expects 12-14 month breakeven.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q4 FY24
Targeting GMV of INR 1,700 crore per quarter and take rate improvement from 4% to 8%.
Mentioned in Q1 FY25, Q2 FY24, Q2 FY25
1,400 new beds in FY26 could drag EBITDA margins by 1-1.2% during ramp-up, though management expects 12-14 month breakeven.
Mentioned in Q2 FY25, Q3 FY24
Management expects 50-60 bps margin expansion for the full year, lower than initial 100-150 bps due to Bangladesh headwinds.
Mentioned in Q1 FY25, Q4 FY24
Apollo HealthCo plans to add 500-550 new offline pharmacy stores in FY25, with Q1 impacted by election delays but pace expected to pick up.
Mentioned in Q2 FY24, Q3 FY24
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
Fast read
Guidance and risk preview
Digital platform expected to achieve EBITDA break-even by end of Q2 or Q3 of next fiscal year, with GMV target of INR 900-1,000 crore.
Bangladesh patient footfall dropped, causing 1.5% revenue impact; management is exploring other international markets but recovery timeline uncertain.
View Risks →